Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aditxt, Inc. (ADTX)

1.36   -0.1 (-6.85%) 01-27 15:59
Open: 1.45 Pre. Close: 1.46
High: 1.5 Low: 1.3
Volume: 130,311 Market Cap: 6(M)

Technical analysis

as of: 2023-01-27 4:42:18 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.78     One year: 2.16
Support: Support1: 1    Support2: 0.83
Resistance: Resistance1: 1.52    Resistance2: 1.85
Pivot: 1.4
Moving Average: MA(5): 1.46     MA(20): 1.39
MA(100): 2.77     MA(250): 9.52
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 58.9     %D(3): 60.8
RSI: RSI(14): 45.6
52-week: High: 28.48  Low: 0.13
Average Vol(K): 3-Month: 214 (K)  10-Days: 203 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADTX ] has closed above bottom band by 34.9%. Bollinger Bands are 90.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.5 - 1.51 1.51 - 1.52
Low: 1.28 - 1.29 1.29 - 1.3
Close: 1.35 - 1.36 1.36 - 1.37

Company Description

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Headline News

Mon, 23 Jan 2023
Is Aditxt Inc (ADTX) a Winner in the Biotechnology Industry? - InvestorsObserver

Fri, 20 Jan 2023
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal ... - StreetInsider.com

Thu, 12 Jan 2023
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock? - Nasdaq

Tue, 03 Jan 2023
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms ... - StreetInsider.com

Tue, 03 Jan 2023
Health Care Sector Update for 01/03/2023: HSTM, ADTX, IMVT - Nasdaq

Fri, 21 Oct 2022
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 4 (M)
% Held by Insiders 3.93e+006 (%)
% Held by Institutions 1.1 (%)
Shares Short 97 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.637e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 138.2
Return on Equity (ttm) -86.4
Qtrly Rev. Growth 853150
Gross Profit (p.s.) 0
Sales Per Share -247.53
EBITDA (p.s.) 19744.5
Qtrly Earnings Growth -1.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -24 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.54

Stock Dividends

Dividend 0
Forward Dividend 82350
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.